Gonadal Function Recovery in Patients With ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
Auteur(s) :
Demeestere, Isabelle [Auteur]
Hôpital Erasme [Bruxelles]
Racape, Judith [Auteur]
Hôpital Erasme [Bruxelles]
Dechene, Julie [Auteur]
Vrije Universiteit Brussel [Bruxelles] [VUB]
Dupuis, Jehan [Auteur]
CHU Henri Mondor [Créteil]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
De Wilde, Virginie [Auteur]
Hôpital Erasme [Bruxelles]
Lazarovici, Julien [Auteur]
Université Paris-Saclay
Institut Gustave Roussy [IGR]
Ghesquieres, Herve [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Touati, Mohamed [Auteur]
CHU Limoges
Sibon, D. [Auteur]
Alexis, M. [Auteur]
Gac, A. C. [Auteur]
Moatti, H. [Auteur]
Virelizier, E. [Auteur]
Maisonneuve, H. [Auteur]
Pranger, D. [Auteur]
Houot, R. [Auteur]
Fornecker, L. M. [Auteur]
Tempescul, A. [Auteur]
André, M. [Auteur]
Casasnovas, R. O. [Auteur]
Hôpital Erasme [Bruxelles]
Racape, Judith [Auteur]
Hôpital Erasme [Bruxelles]
Dechene, Julie [Auteur]
Vrije Universiteit Brussel [Bruxelles] [VUB]
Dupuis, Jehan [Auteur]
CHU Henri Mondor [Créteil]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
De Wilde, Virginie [Auteur]
Hôpital Erasme [Bruxelles]
Lazarovici, Julien [Auteur]
Université Paris-Saclay
Institut Gustave Roussy [IGR]
Ghesquieres, Herve [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Touati, Mohamed [Auteur]
CHU Limoges
Sibon, D. [Auteur]
Alexis, M. [Auteur]
Gac, A. C. [Auteur]
Moatti, H. [Auteur]
Virelizier, E. [Auteur]
Maisonneuve, H. [Auteur]
Pranger, D. [Auteur]
Houot, R. [Auteur]
Fornecker, L. M. [Auteur]
Tempescul, A. [Auteur]
André, M. [Auteur]
Casasnovas, R. O. [Auteur]
Titre de la revue :
Journal of Clinical Oncology
Nom court de la revue :
J Clin Oncol
Numéro :
39
Pagination :
3251-3260
Éditeur :
American Society of Clinical Oncology
Date de publication :
2023-03-26
ISSN :
1527-7755
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, ...
Lire la suite >The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) in early responders on the basis of a positron emission tomography (PET)–driven strategy was safe and minimized toxicity compared with standard 6 BEACOPPescalated cycles. This substudy investigated the benefit of this strategy in gonadal function and fertility in patients under 45 years old. METHODS Ovarian function was assessed by serum measurement of follicle-stimulating hormone (FSH), estradiol, and anti-müllerian hormone in women, and semen analysis, FSH, and testosterone levels were used to evaluate testicular function in men at baseline, end of treatment, and during 5 years of follow-up. RESULTS A total of 145 women and 424 men, enrolled between May 19, 2011, and April 29, 2014, were included. The risk of premature ovarian insufficiency (FSH > 24 IU/L) and of having a low ovarian reserve (anti-müllerian hormone < 0.5 ng/mL) was reduced after treatment in the PET-driven group (odds ratio [OR], 0.20; 95% CI, 0.08 to 0.50; P = .001 and OR, 0.15; 95% CI, 0.04 to 0.56, P = .005, respectively). Both parameters were correlated with age and dose of alkylating agents. However, no significant differences were observed in terms of pregnancy rates. Men in the PET-driven group had a higher recovery rate of sperm parameters after treatment compared with the standard BEACOPPescalated group, as well as a lower risk of severe testicular damage (OR, 0.26; 95% CI, 0.13 to 0.5; P < .0001) and a higher likelihood of achieving pregnancy (OR, 3.7; 95% CI, 1.4 to 9.3; P = .004). CONCLUSION Although both treatments affected ovarian reserve and spermatogenesis, the PET-driven strategy decreased the risk of gonadal dysfunction and infertility in advanced Hodgkin lymphoma.Lire moins >
Lire la suite >The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) in early responders on the basis of a positron emission tomography (PET)–driven strategy was safe and minimized toxicity compared with standard 6 BEACOPPescalated cycles. This substudy investigated the benefit of this strategy in gonadal function and fertility in patients under 45 years old. METHODS Ovarian function was assessed by serum measurement of follicle-stimulating hormone (FSH), estradiol, and anti-müllerian hormone in women, and semen analysis, FSH, and testosterone levels were used to evaluate testicular function in men at baseline, end of treatment, and during 5 years of follow-up. RESULTS A total of 145 women and 424 men, enrolled between May 19, 2011, and April 29, 2014, were included. The risk of premature ovarian insufficiency (FSH > 24 IU/L) and of having a low ovarian reserve (anti-müllerian hormone < 0.5 ng/mL) was reduced after treatment in the PET-driven group (odds ratio [OR], 0.20; 95% CI, 0.08 to 0.50; P = .001 and OR, 0.15; 95% CI, 0.04 to 0.56, P = .005, respectively). Both parameters were correlated with age and dose of alkylating agents. However, no significant differences were observed in terms of pregnancy rates. Men in the PET-driven group had a higher recovery rate of sperm parameters after treatment compared with the standard BEACOPPescalated group, as well as a lower risk of severe testicular damage (OR, 0.26; 95% CI, 0.13 to 0.5; P < .0001) and a higher likelihood of achieving pregnancy (OR, 3.7; 95% CI, 1.4 to 9.3; P = .004). CONCLUSION Although both treatments affected ovarian reserve and spermatogenesis, the PET-driven strategy decreased the risk of gonadal dysfunction and infertility in advanced Hodgkin lymphoma.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T03:04:44Z
2023-09-27T07:09:45Z
2023-09-27T07:09:45Z